Urinary urgency outcomes after propiverine treatment for an overactive bladder

The 'Propiverine study on overactive bladder including urgency data'

Kyu Sung Lee, Hye Won Lee, Myung Soo Choo, Jae Seung Paick, Jeong Gu Lee, Ju Tae Seo, Jeong Zoo Lee, Young Suk Lee, Hana Yoon, Choal Hee Park, Yong Gil Na, Young Beom Jeong, Jong Bouk Lee, Won Hee Park

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Study Type - Therapy (RCT) Level of Evidence 1b Objective To investigate the effects of a daily regimen of propiverine 20 mg in patients with an overactive bladder (OAB), focused on improving urgency, as the clinical efficacy of treatment for OAB should be measured in terms of urgency, the cornerstone symptom of OAB. Patients and Methods Eligible patients aged ≥18 years with symptoms of OAB were enrolled in this multicentre, prospective, parallel, double-blind, placebo-controlled trial. Of 264 patients (mean age 52.2 years), 221 who had efficacy data available from baseline and at least one on-treatment visit with >75% compliance with medication were analysed (142 in the propiverine group and 79 in the placebo group). All patients were randomized to receive a placebo or 20 mg propiverine once daily in a 12-week study. They completed a 3-day voiding diary before visits during the study period, including the severity of urgency associated with every voiding, using the Indevus Urgency Severity Scale and the Urgency Perception Score. The patients' overall self-evaluation of treatment benefits at the end of the study, and safety data, were also collected. Results The daily urgency episodes reduced significantly from baseline to 12 weeks on propiverine treatment, compared with placebo (-46.0% vs -31.3%, P = 0.005). Secondary endpoints, including sum of urgency severity per 24 h, urgency severity per void, and daytime voiding frequency, were also improved significantly in the propiverine group. Overall, of those patients treated with propiverine, 38.7% rated their treatment as providing 'much benefit', compared with 15.2% of the placebo group (P = 0.025). Adverse events reported by 32 (22.5%) and 10 (12.7%) patients in the propiverine and placebo group were all tolerable. However, this is a short-term study using only one fixed regimen. Conclusions Propiverine 20 mg once-daily could be an effective treatment for patients with OAB, by improving urgency.

Original languageEnglish
Pages (from-to)1565-1570
Number of pages6
JournalBJU International
Volume105
Issue number11
DOIs
Publication statusPublished - 2010 Jun 1

Fingerprint

Overactive Urinary Bladder
Placebos
Therapeutics
propiverine
Diagnostic Self Evaluation
Medication Adherence
Safety

Keywords

  • Overactive bladder
  • Propiverine hydrochloride
  • Randomized trial
  • Urinary urgency

ASJC Scopus subject areas

  • Urology

Cite this

Urinary urgency outcomes after propiverine treatment for an overactive bladder : The 'Propiverine study on overactive bladder including urgency data'. / Lee, Kyu Sung; Lee, Hye Won; Choo, Myung Soo; Paick, Jae Seung; Lee, Jeong Gu; Seo, Ju Tae; Lee, Jeong Zoo; Lee, Young Suk; Yoon, Hana; Park, Choal Hee; Na, Yong Gil; Jeong, Young Beom; Lee, Jong Bouk; Park, Won Hee.

In: BJU International, Vol. 105, No. 11, 01.06.2010, p. 1565-1570.

Research output: Contribution to journalArticle

Lee, KS, Lee, HW, Choo, MS, Paick, JS, Lee, JG, Seo, JT, Lee, JZ, Lee, YS, Yoon, H, Park, CH, Na, YG, Jeong, YB, Lee, JB & Park, WH 2010, 'Urinary urgency outcomes after propiverine treatment for an overactive bladder: The 'Propiverine study on overactive bladder including urgency data'', BJU International, vol. 105, no. 11, pp. 1565-1570. https://doi.org/10.1111/j.1464-410X.2009.09050.x
Lee, Kyu Sung ; Lee, Hye Won ; Choo, Myung Soo ; Paick, Jae Seung ; Lee, Jeong Gu ; Seo, Ju Tae ; Lee, Jeong Zoo ; Lee, Young Suk ; Yoon, Hana ; Park, Choal Hee ; Na, Yong Gil ; Jeong, Young Beom ; Lee, Jong Bouk ; Park, Won Hee. / Urinary urgency outcomes after propiverine treatment for an overactive bladder : The 'Propiverine study on overactive bladder including urgency data'. In: BJU International. 2010 ; Vol. 105, No. 11. pp. 1565-1570.
@article{c4d4904abd604d77bd2433c7cc63d00e,
title = "Urinary urgency outcomes after propiverine treatment for an overactive bladder: The 'Propiverine study on overactive bladder including urgency data'",
abstract = "Study Type - Therapy (RCT) Level of Evidence 1b Objective To investigate the effects of a daily regimen of propiverine 20 mg in patients with an overactive bladder (OAB), focused on improving urgency, as the clinical efficacy of treatment for OAB should be measured in terms of urgency, the cornerstone symptom of OAB. Patients and Methods Eligible patients aged ≥18 years with symptoms of OAB were enrolled in this multicentre, prospective, parallel, double-blind, placebo-controlled trial. Of 264 patients (mean age 52.2 years), 221 who had efficacy data available from baseline and at least one on-treatment visit with >75{\%} compliance with medication were analysed (142 in the propiverine group and 79 in the placebo group). All patients were randomized to receive a placebo or 20 mg propiverine once daily in a 12-week study. They completed a 3-day voiding diary before visits during the study period, including the severity of urgency associated with every voiding, using the Indevus Urgency Severity Scale and the Urgency Perception Score. The patients' overall self-evaluation of treatment benefits at the end of the study, and safety data, were also collected. Results The daily urgency episodes reduced significantly from baseline to 12 weeks on propiverine treatment, compared with placebo (-46.0{\%} vs -31.3{\%}, P = 0.005). Secondary endpoints, including sum of urgency severity per 24 h, urgency severity per void, and daytime voiding frequency, were also improved significantly in the propiverine group. Overall, of those patients treated with propiverine, 38.7{\%} rated their treatment as providing 'much benefit', compared with 15.2{\%} of the placebo group (P = 0.025). Adverse events reported by 32 (22.5{\%}) and 10 (12.7{\%}) patients in the propiverine and placebo group were all tolerable. However, this is a short-term study using only one fixed regimen. Conclusions Propiverine 20 mg once-daily could be an effective treatment for patients with OAB, by improving urgency.",
keywords = "Overactive bladder, Propiverine hydrochloride, Randomized trial, Urinary urgency",
author = "Lee, {Kyu Sung} and Lee, {Hye Won} and Choo, {Myung Soo} and Paick, {Jae Seung} and Lee, {Jeong Gu} and Seo, {Ju Tae} and Lee, {Jeong Zoo} and Lee, {Young Suk} and Hana Yoon and Park, {Choal Hee} and Na, {Yong Gil} and Jeong, {Young Beom} and Lee, {Jong Bouk} and Park, {Won Hee}",
year = "2010",
month = "6",
day = "1",
doi = "10.1111/j.1464-410X.2009.09050.x",
language = "English",
volume = "105",
pages = "1565--1570",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Urinary urgency outcomes after propiverine treatment for an overactive bladder

T2 - The 'Propiverine study on overactive bladder including urgency data'

AU - Lee, Kyu Sung

AU - Lee, Hye Won

AU - Choo, Myung Soo

AU - Paick, Jae Seung

AU - Lee, Jeong Gu

AU - Seo, Ju Tae

AU - Lee, Jeong Zoo

AU - Lee, Young Suk

AU - Yoon, Hana

AU - Park, Choal Hee

AU - Na, Yong Gil

AU - Jeong, Young Beom

AU - Lee, Jong Bouk

AU - Park, Won Hee

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Study Type - Therapy (RCT) Level of Evidence 1b Objective To investigate the effects of a daily regimen of propiverine 20 mg in patients with an overactive bladder (OAB), focused on improving urgency, as the clinical efficacy of treatment for OAB should be measured in terms of urgency, the cornerstone symptom of OAB. Patients and Methods Eligible patients aged ≥18 years with symptoms of OAB were enrolled in this multicentre, prospective, parallel, double-blind, placebo-controlled trial. Of 264 patients (mean age 52.2 years), 221 who had efficacy data available from baseline and at least one on-treatment visit with >75% compliance with medication were analysed (142 in the propiverine group and 79 in the placebo group). All patients were randomized to receive a placebo or 20 mg propiverine once daily in a 12-week study. They completed a 3-day voiding diary before visits during the study period, including the severity of urgency associated with every voiding, using the Indevus Urgency Severity Scale and the Urgency Perception Score. The patients' overall self-evaluation of treatment benefits at the end of the study, and safety data, were also collected. Results The daily urgency episodes reduced significantly from baseline to 12 weeks on propiverine treatment, compared with placebo (-46.0% vs -31.3%, P = 0.005). Secondary endpoints, including sum of urgency severity per 24 h, urgency severity per void, and daytime voiding frequency, were also improved significantly in the propiverine group. Overall, of those patients treated with propiverine, 38.7% rated their treatment as providing 'much benefit', compared with 15.2% of the placebo group (P = 0.025). Adverse events reported by 32 (22.5%) and 10 (12.7%) patients in the propiverine and placebo group were all tolerable. However, this is a short-term study using only one fixed regimen. Conclusions Propiverine 20 mg once-daily could be an effective treatment for patients with OAB, by improving urgency.

AB - Study Type - Therapy (RCT) Level of Evidence 1b Objective To investigate the effects of a daily regimen of propiverine 20 mg in patients with an overactive bladder (OAB), focused on improving urgency, as the clinical efficacy of treatment for OAB should be measured in terms of urgency, the cornerstone symptom of OAB. Patients and Methods Eligible patients aged ≥18 years with symptoms of OAB were enrolled in this multicentre, prospective, parallel, double-blind, placebo-controlled trial. Of 264 patients (mean age 52.2 years), 221 who had efficacy data available from baseline and at least one on-treatment visit with >75% compliance with medication were analysed (142 in the propiverine group and 79 in the placebo group). All patients were randomized to receive a placebo or 20 mg propiverine once daily in a 12-week study. They completed a 3-day voiding diary before visits during the study period, including the severity of urgency associated with every voiding, using the Indevus Urgency Severity Scale and the Urgency Perception Score. The patients' overall self-evaluation of treatment benefits at the end of the study, and safety data, were also collected. Results The daily urgency episodes reduced significantly from baseline to 12 weeks on propiverine treatment, compared with placebo (-46.0% vs -31.3%, P = 0.005). Secondary endpoints, including sum of urgency severity per 24 h, urgency severity per void, and daytime voiding frequency, were also improved significantly in the propiverine group. Overall, of those patients treated with propiverine, 38.7% rated their treatment as providing 'much benefit', compared with 15.2% of the placebo group (P = 0.025). Adverse events reported by 32 (22.5%) and 10 (12.7%) patients in the propiverine and placebo group were all tolerable. However, this is a short-term study using only one fixed regimen. Conclusions Propiverine 20 mg once-daily could be an effective treatment for patients with OAB, by improving urgency.

KW - Overactive bladder

KW - Propiverine hydrochloride

KW - Randomized trial

KW - Urinary urgency

UR - http://www.scopus.com/inward/record.url?scp=77952208157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952208157&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2009.09050.x

DO - 10.1111/j.1464-410X.2009.09050.x

M3 - Article

VL - 105

SP - 1565

EP - 1570

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 11

ER -